BR112015005738A2 - formulações orais de angiotensina - Google Patents

formulações orais de angiotensina

Info

Publication number
BR112015005738A2
BR112015005738A2 BR112015005738A BR112015005738A BR112015005738A2 BR 112015005738 A2 BR112015005738 A2 BR 112015005738A2 BR 112015005738 A BR112015005738 A BR 112015005738A BR 112015005738 A BR112015005738 A BR 112015005738A BR 112015005738 A2 BR112015005738 A2 BR 112015005738A2
Authority
BR
Brazil
Prior art keywords
formulations
angiotensin
oral
oral angiotensin
present
Prior art date
Application number
BR112015005738A
Other languages
English (en)
Inventor
Vryhof Austin
Franklin Richard
Stern William
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of BR112015005738A2 publication Critical patent/BR112015005738A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

abstract the present invention provides various formulations for oral delivery of angiotensin peptides. tradução do resumo resumo formulações orais de angiotensina a presente invenção fornece várias formulações para distribuição oral de peptídeos angiotensina.
BR112015005738A 2012-09-17 2013-09-17 formulações orais de angiotensina BR112015005738A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701972P 2012-09-17 2012-09-17
PCT/US2013/060139 WO2014043693A1 (en) 2012-09-17 2013-09-17 Oral formulations of angiotensin

Publications (1)

Publication Number Publication Date
BR112015005738A2 true BR112015005738A2 (pt) 2017-08-08

Family

ID=50278763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005738A BR112015005738A2 (pt) 2012-09-17 2013-09-17 formulações orais de angiotensina

Country Status (13)

Country Link
US (1) US20150246093A1 (pt)
EP (1) EP2895154A4 (pt)
JP (1) JP2015529684A (pt)
KR (1) KR20150065736A (pt)
CN (1) CN104853749A (pt)
AU (1) AU2013315004A1 (pt)
BR (1) BR112015005738A2 (pt)
CA (1) CA2884792A1 (pt)
HK (1) HK1213785A1 (pt)
IN (1) IN2015DN03132A (pt)
MX (1) MX2015003407A (pt)
RU (1) RU2015108678A (pt)
WO (1) WO2014043693A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115082A1 (en) * 2015-01-12 2016-07-21 Enteris Biopharma, Inc. Solid oral dosage forms
WO2017049140A2 (en) * 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
TW202330014A (zh) * 2021-10-13 2023-08-01 日商中外製藥股份有限公司 含有胜肽化合物及界面活性劑之組成物
WO2023214509A1 (ja) * 2022-05-02 2023-11-09 中外製薬株式会社 界面活性剤と併用するためのペプチド化合物を含む組成物
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7375073B2 (en) * 2002-02-27 2008-05-20 Wake Forest University Health Sciences Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
US20080199434A1 (en) * 2006-11-13 2008-08-21 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of cardiovascular conditions
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
BRPI0800585B8 (pt) * 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
RU2589823C2 (ru) * 2009-04-09 2016-07-10 Алкермес Фарма Айэленд Лимитед Композиция для доставки лекарственных средств
PT2536422E (pt) * 2011-02-02 2014-07-18 Univ Southern California Métodos para o tratamento de úlceras do pé diabético

Also Published As

Publication number Publication date
JP2015529684A (ja) 2015-10-08
EP2895154A4 (en) 2016-04-20
HK1213785A1 (zh) 2016-07-15
CN104853749A (zh) 2015-08-19
KR20150065736A (ko) 2015-06-15
US20150246093A1 (en) 2015-09-03
RU2015108678A (ru) 2016-11-10
MX2015003407A (es) 2015-10-14
IN2015DN03132A (pt) 2015-10-02
EP2895154A1 (en) 2015-07-22
WO2014043693A1 (en) 2014-03-20
CA2884792A1 (en) 2014-03-20
AU2013315004A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
CY1123865T1 (el) Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου
HK1224178A1 (zh) 環肽作為蛋白質靶向劑
CO7061035A2 (es) Péptido de tránsito al cloroplasto
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34581A (es) Dispositivo de inhalación para fármacos en polvo
MX340259B (es) Formulaciones de testosterona.
HK1204973A1 (en) Diclofenac formulations
MY168300A (en) Pharmaceutical Composition for Inhalation
BR112014003027A2 (pt) formulação herbicida melhorada
EP2934482A4 (en) ADMINISTRATIVE FORMULATIONS
TN2014000136A1 (en) Selective androgen receptor modulators
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
HK1216720A1 (zh) 用於遞送治療劑的可生物蝕解的硅基組合物
BR112014029157A2 (pt) carregador de pistola curvado lateralmente
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CO7020895A2 (es) Dispositivo de inhalación para fármacos en polvo
BR112015005738A2 (pt) formulações orais de angiotensina
ZA201405857B (en) Direction active projection
UY34286A (es) Diagnóstico de vacuna mejorado
HK1216715A1 (zh) 基於血紅蛋白衍生肽的新型藥物組合物
MY165088A (en) Pharmaceutical compositions comprising alisporivir
CO7020896A2 (es) Dispositivo de inhalación para fármacos en polvo
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
BR112013033052A2 (pt) formulações de entrega de fármaco

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/20 (2006.01), A61K 38/08 (2006.01), A61K 47